- Home
- FENC vs JRVR Comparison
FENC vs JRVR Comparison
Compare FENC & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- JRVR
- Stock Information
- Founded
- FENC 1996
- JRVR 2002
- Country
- FENC United States
- JRVR Bermuda
- Employees
- FENC N/A
- JRVR N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- JRVR Property-Casualty Insurers
- Sector
- FENC Health Care
- JRVR Finance
- Exchange
- FENC Nasdaq
- JRVR Nasdaq
- Market Cap
- FENC 225.4M
- JRVR 259.4M
- IPO Year
- FENC 2001
- JRVR 2005
- Fundamental
- Price
- FENC $8.36
- JRVR $5.72
- Analyst Decision
- FENC Strong Buy
- JRVR Buy
- Analyst Count
- FENC 2
- JRVR 4
- Target Price
- FENC $13.50
- JRVR $6.06
- AVG Volume (30 Days)
- FENC 56.4K
- JRVR 178.0K
- Earning Date
- FENC 08-14-2025
- JRVR 08-04-2025
- Dividend Yield
- FENC N/A
- JRVR 0.69%
- EPS Growth
- FENC N/A
- JRVR N/A
- EPS
- FENC N/A
- JRVR N/A
- Revenue
- FENC $33,302,000.00
- JRVR $665,342,000.00
- Revenue This Year
- FENC $0.85
- JRVR $1.95
- Revenue Next Year
- FENC $55.16
- JRVR $6.80
- P/E Ratio
- FENC N/A
- JRVR N/A
- Revenue Growth
- FENC N/A
- JRVR N/A
- 52 Week Low
- FENC $3.96
- JRVR $3.00
- 52 Week High
- FENC $9.42
- JRVR $7.80
- Technical
- Relative Strength Index (RSI)
- FENC 48.45
- JRVR 50.44
- Support Level
- FENC $7.17
- JRVR $5.52
- Resistance Level
- FENC $9.42
- JRVR $6.04
- Average True Range (ATR)
- FENC 0.54
- JRVR 0.30
- MACD
- FENC 0.02
- JRVR 0.01
- Stochastic Oscillator
- FENC 52.89
- JRVR 52.27
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.